Healthcare entity

National Institute of Industrial Property (INPI)

organization

All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention RECCE® 327, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 5.8 in the same window.

Last mentioned: Mar 24, 2026

Entity pulse

Recent coverage · National Institute of Industrial Property (INPI)

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about National Institute of Industrial Property (INPI)

All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention RECCE® 327, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. National Institute of Industrial Property (INPI) appears in 1 tracked Healthcare story from March 24, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering National Institute of Industrial Property (INPI). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Brazil Patent Grant

    INPI grants patent for Recce's anti-infectives platform.

  2. Clinical Progress

    Ongoing Phase I/II trials for RECCE® 327 in sepsis and burn wounds.

  3. Global IP Expansion

    Recce secures similar patent protections in the US, EU, and Japan.

Stories mentioning National Institute of Industrial Property (INPI) 1

Health Policy Neutral

Recce Secures Critical Brazil Patent for Synthetic Anti-Infective Platform

Recce Pharmaceuticals has been granted a key patent in Brazil for its synthetic anti-infectives platform, covering the manufacturing process for its lead candidates. This move secures intellectual property protection in South America's largest economy, bolstering the company's global strategy against antimicrobial resistance.

2 sources

National Institute of Industrial Property (INPI) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.